On the 12th, the latest announcement on the CDE website indicated that Zelgen's application for the listing of a new class 1 drug, Donafenib tosylate tablets, will be included in the priority review. The proposed indication for this application is for the treatment of late stage (inoperable or metastatic) Hepatocellular carcinoma.
正在翻译中..